搜索

Ab&B Bio-Tech CO.,LTD.JS Ab&B Bio-Tech CO.,LTD.JS
Ab&B Bio-Tech CO.,LTD.JS Ab&B Bio-Tech CO.,LTD.JS
Ab&B Bio-Tech CO.,LTD.JS Ab&B Bio-Tech CO.,LTD.JS

Why Choose Us?

Let China use globally innovative vaccines, and let the world use high-quality vaccines from China!

quanfu quanfu

Strong Corporate Strength

The registered capital is 360 million yuan, the investment in Phase I project is 500 million yuan, the investment in Phase II project is 500 million yuan, and the new investment in Phase III is 2 billion yuan

quanfu quanfu

Products & Services

Committed to the research and development, registration and application, industrial production and sales of innovative vaccines for human use, targeting international standards, and conducting independent innovative research and development.

quanfu quanfu

Scientific Research Capability

Shanghai/Taizhou R&D Center and pilot platform are promoting multiple viral vaccines, bacterial vaccines, conjugate vaccines, recombinant subunit vaccines, and mRNA vaccine pipelines simultaneously.

Product Pipelines

Caring for life, protecting health, and making global technological innovation vaccines are the mission of Ab&B Bio

Quadrivalent Subunit Influenza Vaccine（0.5ml）

Quadrivalent Subunit Influenza Vaccine（0.5ml）

Quadrivalent Subunit Influenza Vaccine: the components of the 2018-2019 northern hemisphere tetravalent influenza vaccine recommended by WHO are: A / Michigan / 45 / 2015 (H1N1) pdm09 similar strain, a / Singapore / infimh-16-0019 / 2016 (H3N2) similar strain, B / Colorado / 06 / 2017 (Victoria strain) similar strain and B / Phuket / 3073 / 2013 (Yamagata strain).

More Product Series

News Center

The launch ceremony of the quadrivalent influenza virus subunit vaccine Huierkangxin was successfully held!
2023-09-26

　9月25日，江苏中慧元通生物科技股份有限公司(以下简称“中慧生物”)四价流感病毒亚单位疫苗慧尔康欣的首发仪式成功举行。
→

The launch meeting of the safety evaluation research project for the tetravalent influenza virus subunit vaccine after its launch was a complete success
2023-09-25

Recently, the launch meeting of the post market safety evaluation research project for the quadrivalent influenza virus subunit vaccine of Jiangsu Zhonghui Yuantong Biotechnology Co., Ltd. was held in Lanzhou, Gansu. The post marketing safety evaluation research project of the tetravalent influenza virus subunit vaccine is a multicenter study led by the Jiangsu Provincial Center for Disease Prevention and Control, guided by the Jiangsu Provincial Center for Adverse Drug Reaction Monitoring, and jointly participated by the six provincial centers for disease prevention and control. The aim is to evaluate the safety of the tetravalent influenza virus subunit vaccine after vaccination in an expanded population of 3 years old and above, Improve the post market safety monitoring model of vaccines in China, establish a long-term active monitoring mechanism, and promote the vaccine regulatory system to move towards higher maturity goals.
→

Launch | Zhonghui Biological Tetravalent Influenza Virus Subunit Vaccine Approved for Launch
2023-05-18

Approved for listing Recently, Jiangsu Zhonghui Yuantong Biotechnology Co., Ltd. (hereinafter referred to as "Zhonghui Bio") independently developed a full-dose unadjuvanted quadrivalent influenza virus subunit vaccine (Huier Kangxin HRK- X®) marketing application has been approved by China National Medical Products Administration (NMPA), which is the first quadrivalent influenza virus subunit vaccine approved for marketing in China.
→

Have a project？Get a touch!

Caring for life, protecting health, and making global technological innovation vaccines are the mission of Ab&B Bio

Contact

E-mail:info@abbbio.com.cn
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City

Quick view

Follow us

Copyright © 2022 Ab&B Bio-Tech CO.,LTD.JS All Rights Reserved.   Powered by:www.300.cn
Verification 苏ICP备16005775号-1
Search